Highlight
• GLP-1 receptor agonists (GLP-1RAs) demonstrate strong preclinical evidence for anti-inflammatory and osteoprotective effects on periodontal and peri-implant tissues.
• Clinical data on dental outcomes with GLP-1RAs is minimal, with only one retrospective cohort study available.
• Oral side effects such as xerostomia, dysgeusia, and anosmia are reported, potentially linked to GLP-1RA pharmacology, notably semaglutide.
• Gastrointestinal side effects raise plausible risks for dental erosion and caries, necessitating further clinical research.
• The interplay between GLP-1 signaling and oral microbiota adds complexity and suggests microbiome-mediated modulation of drug effects.
